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Abstract  
Objectives: Fuzzy trace theory was used to examine the effect of information concerning 
medication benefits and side-effects on willingness to use a hypothetical medication.   
Methods: Participants (N=999) were recruited via Amazon Mechanical Turk. Using 3 x 5 
experimental research design, each participant viewed information about medication side effects 
in 1 of 3 formats and information about medication benefits in 1 of 5 formats.  For both side-
effects and benefits, one format presented only non-numeric information and the remaining 
formats presented numeric information.   Results: Individuals in the non-numeric side-effect 
condition were less likely to take the medication than those in the numeric conditions (p < 
0.0001). In contrast, individuals in the non-numeric benefit condition were more likely to take 
the medication than those in the numeric conditions (p < 0.0001).  Conclusions: Our findings 
suggest that non-numeric side-effect information conveys the gist that the medication can cause 
harm, decreasing willingness to use the medication; whereas non-numeric benefit information 
has the opposite effect. Practice Implications: Presenting side-effect and benefit information in 
non-numeric format appears to bias decision-making in opposite directions. Providing numeric 
information for both benefits and side-effects may enhance decision-making. However, 
providing numeric benefit information may decrease adherence, creating ethical dilemmas for 
providers. 
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1. Introduction 
Medications play an important role in the management of many acute and chronic health 
conditions. Global spending for medications was estimated at $989 Billion (US$) in 2013 and is 
projected to reach $1.3 Trillion in 2018 [1]. Used appropriately, medications can reduce 
morbidity and mortality rates. However, all medications also have the potential to cause harm 
(e.g., unpleasant side effects, allergic reactions) and most carry some risk of serious adverse 
effects. Principles of informed consent, informed and shared decision-making, and professional 
ethics all emphasize WKHLPSRUWDQFHRISDWLHQWV¶XQderstanding the potential harms and benefits 
of recommended therapies [2-5]. To help achieve this goal, many countries require that patients 
be given written medication information (WMI), usually in leaflet form, when they obtain a 
licensed medication [6-8]. However,  patients often have difficulty understanding and using this 
information [9-12].  
In the US and across the European Union, most WMI provided to patients with 
prescription medications contains limited information on the probability of harms and benefits. 
For example, information available for atorvastatin in the USA, a medication used to treat 
hypercholesterolemia, contains the statement: ³This drug may cause muscle pain, tenderness, or 
weakness. Sometimes, a very bad muscle problem may happen that may lead to kidney problems. 
Rarely, deaths have happened in people who get these problems when taking drugs like this 
one.´[13] However, the probability of these events is not provided. Similarly, limited numeric 
information is typically provided on the probability of benefit. For example, the same WMI for 
DWRUYDVWDWLQFRQWDLQVWKHKHDGHU³What is this drug used for?´IROORZHGE\DOLVWRIEXOOet points 
WKDWLQFOXGH³It is used to prevent heart attacks´DQG³It is used to prevent strokes.´+RZHYHUQR
information is provided about the extent to which the risk of heart attacks and strokes is reduced 
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by using this medication. In countries of the European Union, most WMI contain some numeric 
information for medication harms, but still lack numeric benefit information [14, 15].  
Efforts are ongoing in many countries to improve the usability of WMI [16-19]. 
Considerable research has examined the effect that different message formats have on 
comprehension of harms and benefits; on risk perceptions; and on behavioral intentions [20, 21]. 
People are more likely to overestimate medication harms when presented using a non-numeric 
format rather than a numeric one [22-27]. Another study demonstrated that provision of numeric 
information increases willingness to use a hypothetical medication compared to non-numeric 
formats [28]. However, there is no consensus concerning the best numeric format to use  [21, 
29]. Much less research has focused on how to best convey information about medication 
benefits, although there is evidence that patients tend to overestimate the likelihood of benefit 
[30, 31]. Another study found that providing numeric information on medication benefits 
corrected overestimates and reduced willingness to use the medication [32]. 
 Much of the research on medication harm and benefit communication has been 
atheoretical [29]. Consequently, it is hard to explain why people appear to overestimate 
medication harms and benefits in the absence of numeric information. In this paper, we report 
the results of a study designed to test predictions derived from fuzzy trace theory (FTT) 
concerning the differential effects of numeric and non-numeric information about medication 
harms and benefits on willingness to use a medication and perceptions of safety and 
effectiveness [33-35]. Briefly, FTT is a dual-process model of memory, reasoning, judgment and 
decision-making that has been used to study how people make decisions involving uncertainty. 
FTT posits that, when an individual is exposed to any meaningful stimulus (e.g., WMI), two 
types of representations are encoded in memory, a verbatim representation and one or more gist 
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representations. Verbatim representations capture the exact words, numbers, or images included 
in the stimulus, whereas gist representations capture the essential, bottom-line meaning of the 
stimulus to the person, including its emotional meaning [33]. Multiple gist representations may 
be encoded in response to the same stimulus, including relatively crude categorical gist 
representations (e.g., that the medication may cause serious side effects) and somewhat more 
precise ordinal gist representations (e.g., the risk of the medication causing serious side effects is 
low). A central tenet of FTT is that gist representations are retained in memory longer than 
verbatim representations and are more easily accessed when needed to make decisions. 
Therefore, when making judgments and decisions, people tend to rely on gist representations, 
unless the task requires recall of more precise information.  
Within the context of the current study, FTT predicts that when individuals are presented 
with non-numeric side effect information, they are likely to form the categorical gist 
representation that taking the medication can cause harm, leading to risk avoidance (i.e., reduced 
willingness to use the medication). In contrast, when individuals are presented with non-numeric 
benefit information, FTT predicts that they are likely to form the categorical gist representation 
that taking the medication can help, leading to greater willingness to use the medication. 
Addition of numbers to the format allows individuals to extract somewhat more precise gist 
representations (e.g., not everyone who takes the medication is harmed or benefits from 
treatment). In the case of side-effect information, this more precise gist representation would 
promote greater willingness to use the medication; but, numeric benefit information would have 
the opposite effect. To test these predictions, we presented individuals with written information 
concerning the potential harms and benefits associated with a hypothetical medication used to 
treat high cholesterol. The format of the information was varied systematically across 
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experimental groups. Participants received information either in a numeric or a non-numeric 
format. In addition, the numeric formats varied the probability of medication harms and benefits. 
Based on FTT, we predicted that individuals would be less willing to use the medication when 
(1) harms were presented in non-numeric format and (2) benefits were presented in numeric 
format. We also predicted that willingness to take the medication would not vary as a function of 
the probability of either medication harms or benefits. Thus, we are suggesting the difference in 
how people respond to numeric versus non-numeric harm and benefit information is a function 
of the presence of numbers in the numeric format rather than their precise value..  
2. Materials and Methods 
 To recruit participants, we posted a link to the survey on Amazon Mechanical Turk 
(www.mturk.com) [36]. The title of the survey linNZDV³$QVZHUDVXUYH\DERXWSUHVFULSWLRQ
PHGLFDWLRQLQIRUPDWLRQ´$WRWDORI,070 individuals accessed the link to the survey, which was 
administered via Qualtrics® software, and agreed to participate in the study. However, 71 of 
these individuals failed an attention check question that appeared as the second question in the 
survey ± and we removed these participants from the sample. Thus a total of 999 individuals 
completed the survey. All participants were paid fifty US cents for completing the survey, 
undertaken on May 13, 2015.  
2.1 Experimental Materials 
 The study used a 3 x 5 experimental research design with participants randomized to 
condition. The experimental materials used were adapted from Peters and colleagues [28]. All 
participants were told: ³,PDJLQHWKDW\RXKDYHEHHQGLDJQRVHGZLWKKLJKFKROHVWHURODPDMRU
cause of heart disease and stroke. Your doctor has prescribed you a new medication to lower 
your cholesterol. It can reduce your risk of having a heart attack or stroke, but it has possible 
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side effects. The table below shows how the medication can help and the possible side effects the 
PHGLFDWLRQFDQFDXVH´ Each participant viewed information about medication side effects (SE) 
in 1 of 3 probability-format conditions and medication benefits in 1 of 5 probability-format 
conditions. The 3 side-effect conditions were: 
i. Low SE Probability, Numeric Format;  
ii. High SE Probability, Numeric Format; and  
iii. Non-numeric Format.  
The 5 benefit conditions were: 
i. Low Benefit Probability, Risk With and Without Treatment Numeric Format;  
ii. High Benefit Probability, Risk With and Without Treatment Numeric Format;  
iii. Low Benefit Probability, Risk Difference Numeric Format;  
iv. High Benefit Probability, Risk Difference Numeric Format; and  
v. Non-numeric Benefit Format.  
The frequency of potential harms shown in the high SE probability condition were the same as 
those used by Peters and colleagues except that the risk of the rare serious side-effect (i.e., 
rhabdomyolysis) was doubled (i.e., 2 rather than 1) to avoid the need for fractions in the low SE 
probability condition. The benefit information described the effect of the medication in reducing 
the risk of heart attack or stroke and we used a relevant meta-analysis of trials, to estimate the 
values in the low benefit probability conditions [37]. The estimated benefit was doubled in the 
high benefit conditions. As an example, Figure 1 shows the information presented in the High SE 
Probability, Numeric )RUPDWņ+LJK%HQHILW3UREDELOLW\Risk Difference Numeric Format 
condition. Table 1 provides a description of the information corresponding to each experimental 
condition.  
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2.2 Measures 
2.2.1 Outcome variables. Willingness to take the medication was the primary outcome 
variable, assessed by asking: ³,I\RXKDGKLJKFKROHVWHURODQG\RXUGRFWRUSUHVFULEHGWKLV
PHGLFDWLRQIRU\RXKRZOLNHO\LVLWWKDW\RXZRXOGWDNHLW"´ Responses were recorded on a 7-
point scale ranging from 0=Very unlikely to 6=Very likely. Participants were also asked to 
indicate the most important reason for their response using an established measure [XX]. Options 
provided were: a) most of the adverse events are not very serious; b) any serious adverse events 
are very unlikely; c) prefer to avoid taking medications and will do something else; d) there are 
too many possible adverse events; e) a lot of people will experience at least one of the adverse 
events, and I don't want to be one of them; f) the very serious muscle damage; g) other; and h) 
none of the above. 
 Five secondary outcome variables were assessed. First, participants were asked to agree 
or disagree with the statement, ³7KHSRWHQWLDOEHQHILWVRIWDNLQJWKLVPHGLFDWLRQRXWZHLJKWKH
poWHQWLDOULVNV´, responding on a 7-point scale (0=Strongly disagree to 6=Strongly agree). 
Second, participants were asked ³+RZVDIHRUGDQJHURXVLVWKLVPHGLFDWLRQ"´ (0=Very 
dangerous to 6=Very safe). Third, participants were asked ³,I\RXKDGKLJKcholesterol and took 
WKLVPHGLFDWLRQKRZOLNHO\LVWKHPHGLFDWLRQWRKHOS\RX"´ Fourth, participants were asked ³,I
you had high cholesterol and took this medication, how likely is the medication to cause side 
HIIHFWV"´ Finally, ³+RZOLNHO\DUH\RXWRUHFommend this medication to somebody else with high 
FKROHVWHURO"´These last three questions were all answered on scales, 0=Very unlikely to 6=Very 
likely. 
2.2.2 Health and Medication Use.  Perceived health status was assessed on a 5-point scale 
(1=Poor to 5=Excellent). Participants were also asked if they were currently taking prescription 
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medications (Yes/No) and whether they had ever experienced a serious medication side effect 
(Yes/No). 
2.2.3 Demographic characteristics.  The following socio-demographic characteristics were 
assessed: age (in years), gender, race (dichotomized as White/Nonwhite), education 
(dichotomized as University Graduate/ Not University Graduate), and self-identified as a health 
care provider (Yes/No). 
2.3 Statistical Analysis 
 All analyses were performed using PC-SAS version 9.4[38].  Descriptive statistics were 
used to summarize participant characteristics. Linear regression was used to assess the effect of 
numeric versus non-numeric side-effect and benefit information on the outcome variables.  A 
separate model was used for each outcome variable. Each regression model controlled for age, 
gender, race, education, health status, current medication use, and experience of serious 
medication side-effects. We also tested for an interaction between the risk and benefit 
information conditions by adding a multiplicative interaction term to each model. Pairwise 
comparisons examined mean differences on the outcome variables among the three risk and five 
benefit conditions. Statistical significance was set at alpha error = 0.05.  
3. Results 
 The mean age of participants (N=999) was 33.9 (SD=11.1). Most participants were male 
(56.4%), white (73.3%), and had graduated from university (56.2%). The percentage of 
participants reporting being in excellent, very good, good, fair, and poor health were 11.6, 39.5, 
35.0, 11.4, and 2.4, respectively. About one-third (31.3%) of participants were currently using a 
prescription medication and 19.7% reported ever experiencing a serious medication side-effect. 
None of these variables differed significantly across the experimental conditions.  
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3.1 Differences between Numeric versus Non-Numeric Conditions 
 In regression analyses, the interaction between the side-effect and benefit format 
conditions was not statistically significant for any of the outcome variables examined. Therefore, 
only main effects of the conditions were examined. As predicted, individuals in both numeric 
side-effect conditions reported being more likely to take the medication, compared to those in the 
non-numeric side-effect condition (Table 2 and Figure 2). This pattern was replicated for all five 
secondary outcomes, with individuals in both numeric side-effect conditions reporting more 
favorable beliefs toward medication use compared to individuals in the non-numeric side-effect 
condition.  
Also as predicted, individuals in all the numeric benefit conditions reported being less 
likely to take the medication compared to those in the non-numeric benefit condition (Table 2 
and Figure 3). However, the difference between the High Benefit, Risk With and Without 
Treatment condition and the non-numeric benefit condition was not statistically significant. In 
addition, compared to individuals in each of the numeric benefit conditions, individuals in the 
non-numeric condition reported that the medication was more likely to help, were more likely to 
agree that medication benefits outweigh the risks, and were more likely to say they would 
recommend the medication to others. This pattern was not replicated for two of the secondary 
outcome variables: medication safety and likelihood of causing side-effects. However, one 
would expect these variables to be less affected by the format of medication benefit information. 
3.2 Differences among the Numeric Side-Effect/Benefit Conditions 
No differences were found between the low and high numeric side-effect conditions for 
any of the outcome variables (Figure 2).  However, some differences were observed among the 
numeric benefit conditions (Figure 3). First, individuals in the High Benefit, Risk With and 
Without Treatment condition reported that the medication was more likely to help, compared to 
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individuals in the other numeric benefit conditions. Second, compared to individuals in both Low 
Benefit conditions, individuals in the High Benefit, Risk With and Without Treatment condition 
reported being more likely to take the medication and to recommend the medication to others, 
and were more likely to agree that medication benefits outweigh the risks. In contrast, no 
differences on any of the outcome variables were observed between the High versus Low Benefit, 
Risk Difference conditions. 
3.3 Relationship between Socio-Demographic Characteristics and Outcome Variables 
As shown in Table 2, several socio-demographic characteristics were significant 
predictors of the outcome variables.  The strongest associations involved race and current 
medication use. Compared to non-white participants, white participants reported being more 
likely to take the medication, perceived the medication as safer, and were less likely to believe 
that the medication would cause side-effects. Compared to participants who were not currently 
using any medications, current medication users reported being more likely to use the 
medication, perceived the medication as safer, were more likely to recommend the medication to 
others, and were more likely to agree that medication benefits outweigh the risks. 
3.4 Reasons for Willingness to Take the Medication 
 Among individuals who reported being unlikely to take the medication (n=247), the most 
common reasons given were:  prefer to avoid taking medications and will do something else 
(30.0%, n=74), there are too many possible adverse events (23.9%, n=59), and the potential for 
very serious muscle damage (23.9%, n=59). Among individuals who reported being likely to 
take the medication (n=682), the most common reasons given were: most of the adverse events 
are not very serious (41.8%, n=285) and any serious adverse events are very unlikely (34.2%, 
n=233). Finally, among individuals who reported being neither likely nor unlikely to take the 
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medication (n=70), the most common reasons given were: prefer to avoid taking medications and 
will do something else (35.7%, n=25), there are too many possible adverse events (24.3%, 
n=17), and the very serious muscle damage (14.3%, n=10). 
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4. Discussion and Conclusion 
4.1 Discussion 
 Most of our predictions, derived from FTT, were supported. As predicted, participants 
were most willing to use the medication when they viewed information about: (1) medication 
harms in a numeric format and (2) medication benefits in the non-numeric format. These effects 
of message format were also reflected in the secondary outcomes. Moreover, willingness to use 
the medication did not vary between the two levels of harm examined, despite the probability of 
side-effects in the high probability condition being twice that of the low probability condition. 
Thus, at least with respect to the harm information, it was the addition of numbers to the 
information provided that changed the gist conveyed, rather than the precise numbers 
themselves. Similarly, varying the probability of benefit did not affect participant judgments 
when the Risk Difference format was used. Participants who were told that 2,250 strokes/heart 
attacks could be prevented by treating 100,000 people with the medication were no more willing 
to use the medication or rate it as more likely to help than participants who were told that only 
1,125 strokes/heart attacks could be prevented in 100,000 people. However, when benefit 
information was presented in the Risk With and Without Treatment format, the probability of 
benefit did make a difference. Here, participants who saw the high probability of benefit message 
were more willing to use the medication than people who saw the low probability of benefit 
message.  
4.1.1 Effects of Information Concerning Potential Medication Harms 
 The prediction that people would be least willing to use the medication when harm 
information was presented using a non-numeric format was based on the notion that when people 
are presented with non-numeric side effect information, they are likely to form the categorical 
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gist representation that taking the medication can cause harm and that the provision of numeric 
side effect information allows them to form more precise gist representations (e.g., only some 
people who take the medication are harmed). However, the reasons participants gave for being 
likely or unlikely to use the medication suggest a slightly different explanation. Over 60% of 
participants identified reasons that mentioned the severity of medication side effects (e.g., the 
potential for very serious muscle damage, that most serious side effects are unlikely, most side 
effects are not serious). This suggests that concerns about the one side effect described as very 
serious (i.e., rhabdomyolysis) was the main influence on participant judgments. Thus, in the non-
numeric condition the salient gist to many participants seemed to be that the medication could 
cause serious harm (a categorical gist representation), but the numeric information supported 
formation of the more precise ordinal gist representation, The risk of the medication causing 
serious harm is low. Although the precise risk of the serious side effect did not affect participant 
judgments, both probability levels were consistent with a very low risk of serious harm (i.e., 1 or 
2 out of 100,000 people treated). If the probability of this side effect had been higher, a 
difference between the low and high probability groups might have been observed.  
4.1.2 Effects of Information Concerning Potential Medication Benefits 
 Our prediction that the mere presence of numbers quantifying the probability of benefit 
would reduce willingness to use the medication was supported. This prediction was based on the 
notion that when people are exposed to benefit information in non-numeric format they tend to 
form the categorical gist representation, Taking the medication can help, increasing willingness 
to use the medication. Addition of numbers to the format supports the formation of more precise 
gist representations (e.g., Only some people who take the medication are helped). When numeric 
benefit information was presented using the Risk Difference format, participant judgments did 
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not vary as a function of the probability of benefit, suggesting that the high and low benefit 
materials conveyed the same gist. However, participant judgments did vary as a function of the 
probability of benefit when numeric benefit information was presented using the Risk With and 
Without Treatment format. In the low benefit condition, where individuals saw the rate of heart 
attack or stroke with treatment as 3.9% and the rate without treatment as 5.0% (values dervied 
from clinical trials), participants were more likely to form the gist representation, Using the 
medication only helps a little. In contrast, in the high benefit condition, where individuals saw 
the rate with treatment as 1.95% and the rate without treatment as 5.0%, participants were more 
likely to form the gist representation, Using the medication  helps a lot. Thus, it appears that the 
Risk With and Without Treatment format is superior to the Risk Difference format in conveying 
meaningful information concerning the probability of benefiting from treatment. 
4.1.3 Limitations  
 The study used a convenience sample and collected data using the Internet. Most 
respondents were healthy young adults and were not currently using any prescription 
medications. Thus, the generalizability of our findings to more representative patient populations 
is unknown. Moreover, the experimental scenarios described a hypothetical medication. The 
extent to which participant responses reflect the actual choices they would make in real life is 
also unknown.  
4.2  Conclusion 
  Despite these limitations, our findings demonstrate the potential value of FTT for 
understanding how people extract meaning from information concerning medication harms and 
benefits. As predicted by FTT, providing numeric information on the probability of side effects 
increased willingness to use the medication; whereas providing numeric information on the 
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probability of benefitting from medication use had the opposite effect. Our findings suggest that 
numbers matter because of the gist they convey and that the absence of numbers also conveys 
gist.  Our findings also highlight the complexity of the medication harm/benefit communication 
process. Additional research, testing theoretically informed predictions, is needed to better 
understand how individuals extract meaningful gist from information concerning potential 
medication harms and benefits and to identify message formats most likely to result in enhanced 
comprehension and decision making. 
4.3 Practice Implications 
 Most current WMI provides little numeric information on the probability of potential harms 
or benefits. Peters and colleagues [28] have called for the inclusion of numeric information on 
side effects in WMI. However, our findings suggest that including side effect information in 
numeric format and benefit information in non-numeric format is likely to result in a substantial 
bias favoring medication use. Alternatively, both types of information could be presented in 
numeric format, as is done in drug facts boxes [32]. Our findings also support using the Risk 
With and Without Treatment format to convey benefit information. This format is used in drug 
facts boxes [32]. However, inclusion of numeric benefit information in WMI is likely to increase 
patient reluctance to initiate and continue therapy, potentially creating ethical dilemmas for 
health care providers.  
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